Molecular effects of paclitaxel: Myths and reality (a critical review)

International Journal of Cancer

Volumn 83, Issue 2, 1999, Pages 151-156

  Blagosklonny, Mikhail V ^a,b   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CYTOPATHOGENIC EFFECT; DRUG EFFECT; ENZYME ACTIVATION; MICROTUBULE; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; ENZYME ACTIVATION; ENZYME INHIBITORS; GENES, P53; HUMANS; MICROTUBULES; MITOSIS; PACLITAXEL;

EID: 0032883001     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5     Document Type: Review

References (96)

1. ALI, S.T., COGGINS, J.R. and JACOBS, H.T., The study of cell-death proteins in the outer mitochondrial membrane by chemical cross-linking. Biochem. J., 325, 321-324 (1997).
2. AMATO, S.F., SWART, J.M., BERG, M., WANEBO, H.J., MEHTA, S.R. and CHILES, T.C., Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res., 58, 241-247 (1998).
3. BARBOULE, N., CHADEBECH, P., BALDIN, V., VIDAL, S. and VALETTE, A., Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell lines. Oncogene, 15, 2867-2875 (1997).
4. BASU, A. and HALDAR, S., Microtubule-damaging drugs triggered Bcl2 phosphorylation - requirement of phosphorylation on both serine-70 and serine-87 residues of Bcl2 protein. Int. J. Oncol., 13, 659-664 (1998).
5. BHALLA, K., IBRADO, A.M., TOURKINA, E., TANG, C., MALONEY, M.E. and HUANG, Y., Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia, 7, 563-568 (1993).
6. BLAGOSKLONNY, M.V., CHUMAN, Y., BERGAN, R.C. and FOJO, T., Mitogen activated protein kinase pathway is dispensible for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia, 13, 1028-1036 (1999).
7. BLAGOSKLONNY, M.V. and EL-DEIRY, W.S., Acute overexpression of wt p53 facilitates anti-cancer drug-induced death of cancer and normal cells. Int. J. Cancer, 75, 933-940 (1998).
8. BLAGOSKLONNY, M.V., GIANNAKAKOU, P., EL-DEIRY, W.S., KINGSTON, D.G.I., HIGGS, P.I., NECKERS, L. and FOJO, T., Raf1/bcl2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57, 130-135 (1997).
9. BLAGOSKLONNY, M.V., SCHULTE, T.W., NGUYEN, P., MIMNAUGH, E.G., TREPEL, J. and NECKERS, L., Taxol induction of p21Waf1 and p53 requires c-raf-1. Cancer Res., 55, 4623-4626 (1995).
10. BLAGOSKLONNY, M.V., SCHULTE, T.W., NGUYEN, P., TREPEL, J. and NECKERS, L., Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res., 56, 1851-1854 (1996).
11. BRISCH, E., DAGGETT, M.A. and SUPRENANT, K.A., Cell cycle-dependent phosphorylation of the 77 kDa echinoderm microtubule-associated protein (EMAP) in vivo and association with the p34cdc2 kinase. J. Cell Sci., 109, 2885-2893 (1996).
12. BURKHART, C.A., BERMAN, J.W., SWINDELL, C.S. and HORWITZ, S.B., Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity. Cancer Res., 54, 5779-5782 (1994).
13. CROSS, S.M., SANCHEZ, C.A., MORGAN, C.A., SCHIMKE, M.K., RAMEL, S., IDZERDA, R.L., RASKIND, W.H. and REID, B.J., A p53-dependent mouse spindle checkpoint. Science, 267, 1353-1356 (1995).
14. DAS, K.C., GUO, X. and WHITE, C.W., Protein kinase Cδ-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anti-cancer drugs. J. biol. Chem., 273, 34639-34645 (1998).
15. DEBERNARDIS, D., SIRE, E.G., DE FEUDIS, P., VIKHANSKAYA, F., VALENTI, M., PARODI, S., D'INCALCI, M. and BROGGINI, M., p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57, 870-874 (1997).
16. DING, A., SANCHEZ, E. and NATHAN, C.F., Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J. Immunol., 151, 5596-5602 (1993).
17. DING, A.H., PORTEU, F., SANCHEZ, E. and NATHAN, C.F., Shared actions of endotoxin and Taxol on TNF-α receptors and TNF-α release. Science, 248, 370-372 (1990).
18. DONALDSON, K.L., GOOLSBY, G., KIENER, P.A. and WAHL, A.F., Activation of p34cdc coincident with Taxol-induced apoptosis. Cell Growth Differentiation, 5, 1041-1050 (1994a).
19. DONALDSON, K.L., GOOLSBY, G.L. and WAHL, A.F., Cytotoxicity of the anti-cancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int. J. Cancer. 57, 847-855 (1994b).
20. FAN, S., CHERNEY, B., REINHOLD, W., RUCKER, K. and O'CONNOR, P.M., Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin. Cancer Res., 4, 1047-1054 (1998).
21. FANG, G., CHANG, B.S., KIM, C.N., PERKINS, C., THOMPSON, C.B. and BHALLA, K.N., "Loop" domain is necessary for Taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting Taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res., 58, 3202-3208 (1998).
22. FRANKEL, A., BUCKMAN, R. and KERBEL, R.S., Abrogation of Taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res., 57, 2388-2393 (1997).
23. FUKASAWA, K. and VANDE WOUDE, G.F., Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol. Cell Biol., 17, 506-518 (1997).
24. GAO, C., ARLINGHAUS, R.B. and SINGH, B., Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells. Oncogene, 12, 1571-1576 (1996).
25. GIANNAKAKOU, P., SACKETT, D.L., KANG, Y.-K., ZHAN, Z., BUTERS, J.T.M., FOJO, T. and PORUCHYNSKY, M.S., Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. biol. Chem., 272, 17118-17125 (1997).
26. GIANNAKAKOU, P., VILLALBA, L., LI, H., PORUCHYNSKY, M. and FOJO, T., Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int. J. Cancer, 75, 57-63 (1998).
27. GLIKSMAN, N.R., PARSONS, S.F. and SALMON, E.D., Okadaic acid induces interphase to mitotic-like microtubule dynamic instability by inactivating rescue. J. Cell Biol., 119, 1271-1276 (1992).
28. HALDAR, S., BASU, A. and CROCE, C.M., Bcl2 is the guardian of microtubule integrity. Cancer Res., 57, 229-233 (1997).
29. HALDAR, S., BASU, A. and CROCE, C.M., Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res., 58, 1609-1615 (1998).
30. HALDAR, S., CHINTAPALLI, J. and CROCE, C.M., Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56, 1253-1255 (1996).
31. HALDAR, S., JENA, N. and CROCE, C.M., Inactivation of Bcl-2 by phosphorylation. Proc. nat. Acad. Sci. (Wash.), 92, 4507-4511 (1995).
32. HAWKINS, D.S., DEMERS, G.W. and GALLOWAY, D.A., Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
33. HORWITZ, S.B., Mechanism of action of Taxol. Trends Pharmacol. Sci., 13, 134-136 (1992).
34. HORWITZ, S.B., SHEN, H.J., HE, L., DITTMAR, P., NEEF, R., CHEN, J. and SCHUBART, U.K., The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. J. biol. Chem., 272, 8129-8132 (1997).
35. HOSHI, M., OHTA, K., GOTOH, Y., MORI, A., MUROFUSHI, H., SAKAI, H. and NISHIDA, E., Mitogen-activated-protein-kinase-catalyzed phosphorylation of microtubule-associated proteins, microtubule-associated protein 2 and microtubule-associated protein 4, induces an alteration in their function. Europ. J. Biochem., 203, 43-52 (1992).
36. HUIZING, M.T., KEUNG, A.C.F., ROSING, H., VAN DER KUIJ, V., TEN BOKKEL HUININK, W.W., MANDJES, I.M., DUBBELMAN, A.C., PINEDO, H.M. and BEIJNEN, J.H., Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. clin. Oncol., 11, 2127-2135 (1993).
37. IBRADO, A.M., LIU, L. and BHALLA, K., Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells. Cancer Res., 57, 1109-1115 (1997).
38. ITO, T., DENG, X., CARR, B. and MAY, W.S., Bcl-2 phosphorylation required for anti-apoptosis function. J. biol. Chem., 272, 11671-11673 (1997).
39. JORDAN, M.A., TOSO, R.J., THROWER, D. and WILSON, L., Mechanism of mitolic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. nat. Acad. Sci. (Wash.), 90, 9552-9556 (1993).
40. JORDAN, M.A., WENDELL, K., GARDINER, S., DERRY, W.B., COPP, H. and WILSON, L., Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res., 56, 816-825 (1996).
41. JORDAN, M.A. and WILSON, L., Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 10, 123-130 (1998).
42. KUNG, A.L., ZETTERBERG, A., SHERWOOD, A.W. and SCHIMKE, R.T., Cytotoxic effects of cell cycle phase specific agents: a result of cell cycle perturbation. Cancer Res., 50, 7307-7314 (1990).
43. LAIRD, A.D., MORRISON, D.K. and SHALLOWAY, D., Characterization of Raf-1 activation in mitosis. J. biol. Chem., 274, 4430-4439 (1999).
44. LAIRD, A.D., TAYLOR, S.J., OBERST, M. and SHALLOWAY, D., Raf-1 is activated during mitosis. J. biol. Chem., 45, 26742-26745 (1995).
45. LANNI, J.S., LOWE, S.W., LICITRA, E.J., LIU, J.O. and JACKS, T., p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. nat. Acad. Sci. (Wash.), 94, 9679-9683 (1997).
46. LARSSON, N., MARKLUND, U., GRADIN, H.M., BRATTSAND, G. and GULLBERG, M., Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol. cell. Biol., 17, 5530-5539 (1997).
47. LEE, L.F., HASKILL, J.S., MUKAIDA, N., MATSUSHIMA, K. and TING, J.P., Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol. cell. Biol., 17, 5097-5105 (1997).
48. LEE, L.-F., SCHUERER-MALY, C.-C., LOFQUIST, A.K., VAN HAAFTEN-DAY, C., TING, J.P.-Y., WHITE, C.M., MARTIN, B.K. and HASKILL, J.S., Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res., 56, 1303-1308 (1996).
49. LING, Y.-H., CONSOLI, U., TORNOS, C., ANDREEFF, M. and PEREZ-SOLER, R., Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int. J. Cancer, 75, 925-932 (1998a).
50. LING, Y.-H., YANG, Y., TORNOS, C., SINGH, B. and PEREZ-SOLER, R., Paclitaxel-induced apoptosis is associated with expression and activation of c-mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res., 58, 3633-3640 (1998b).
51. LONG, B.H. and FAIRCHILD, C.R., Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res., 54, 4355-4361 (1994).
52. LOVRIC, J. and MOELLING, K., Activation of Mil/Raf protein kinase in mitotic cells. Oncogene, 12, 1109-1116 (1996).
53. MANTHEY, C.L., BRANDES, M.E., PERERA, P.Y. and VOGEL, S.N., Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J. Immunol., 149, 2459-2464 (1992).
54. MASSON, D. and KREIS, T.E., Binding of E-MAP-115 to microtubules is regulated by cell cycle-dependent phosphorylation. J. Cell Biol., 131, 1015-1024 (1995).
55. MAUNDRELL, K., ANTONSSON, B., MAGNENAT, E., CAMPS, M., MUDA, M., CHABERT, C., GILLIERON, C., BOSCHERT, U., VIAL-KNECHT, E., MARTINOU, J.-C. and ARKINSTALL, S., Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. biol. Chem., 272, 25238-25242 (1997).
56. MIYASHITA, T. and REED, J.C., Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293-299 (1995).
57. MOOS, P.J. and FITZPATRICK, F.A., Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. nat. Acad. Sci. (Wash.), 95, 3896-3901 (1998).
58. NICHOLSON, K.M., BIBBY, M.C. and PHILLIPS, R.M., Influence of drug exposure on the activity of paclitaxel in multicellular spheroids. Europ. J. Cancer, 33, 1291-1298 (1997).
59. NOGALES, E., WOLF, S.G., KHAN, I.A., LUDUENA, R.F. and DOWNING, K.H., Structure of tubulin at 6.5 Å and location of the Taxol-binding site. Nature (Lond.), 375, 424-427 (1995).
60. O'CONNOR, P.M. AND 12 OTHERS, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anti-cancer Drug Screen and correlations with growth-inhibitory potency of 123 anti-cancer agents. Cancer Res., 57, 4285-4301 (1997).
61. PEREGO, P., ROMANELLI, S., CARENINI, N., MAGNANI, I., LEONE, R., BONETTI, A., PAOLICCHI, A. and ZUNINO, F., Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann. Oncol., 9, 423-430 (1998).
62. PETER, M., SANGHERA, J.S., PELECH, S.L. and NIGG, E.A., Mitogen-activated protein kinases phosphorylate nuclear lamins and display sequence specificity overlapping that of mitotic protein kinase p34cdc2. Europ. J. Biochem., 205, 287-294 (1992).
63. PORUCHYNSKY, M.S., WANG, E.E., RUDIN, C.M., BLAGOSKLONNY, M.V. and FOJO, T., Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res., 58, 3331-3338 (1998).
64. PRESCOTT, D.M., Cellular sites of RNA synthesis. Progr. nucl. Acid Res. mol. Biol., 3, 33-45 (1964).
65. ROWINSKY, E.K., Update on the antitumor activity of paclitaxel in clinical trials. Ann. Pharmacother., 28, S18-S22 (1994).
66. ROWINSKY, E.K. and DONEHOWER, R.C., Paclitaxel (Taxol). N. Engl. J. Med., 332, 1004-1014 (1995).
67. SACKETT, D. and FOJO, T., Taxanes. Cancer Chemother. Biol. Response Modifiers, 17, 59-79 (1997).
68. SAFRAN, H., KING, T., CHOY, H., GOLLERKI, A., KWAKWA, H., LOPEZ, F., COLE, B., MYERS, J., TARPEY, J. and ROSMARIN, A., p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer, 78, 1203-1210 (1996).
69. SCATENA, C.D., STEWART, Z.A., MAYS, D., TANG, L.J., KEEFER, C.J., LEACH, S.D. and PIETENPOL, J.A., Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. biol. Chem., 273, 30777-30784 (1998).
70. SCHIEVELLA, A.R., PAIGE, L.A., JOHNSON, K.A., HILL, D.E. and ERIKSON, R.L., Protein tyrosine phosphatase 1B undergoes mitosis-specific phosphorylation on serine. Cell Growth Differentiation, 4, 239-246 (1993).
71. SCHIFF, P.B. and HORWITZ, S.B., Taxol stabilizes microtubules in mouse fibroblast cells. Proc. nat. Acad. Sci. (Wash.), 77, 1561-1565 (1980).
72. SHIBUYA, E.K. and RUDERMAN, J.V., Mos induces the in vitro activation of mitogen-activated protein kinases in lysates of frog oocytes and mammalian cells. Mol. Biol. Cell, 4, 781-790 (1993).
73. SONTAG, E., NUNBHAKDI-CRAIG, V., BLOOM, G.S. and MUMBY, M.C., A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J. Cell Biol., 128, 1131-1144 (1995).
74. SORGER, P.K., DOBLES, M., TOURNEBIZE, R. and HYMAN, A.A., Coupling cell division and cell death to microtubule dynamics. Curr. Opin. Cell Biol., 9, 807-814 (1997).
75. SRIVASTAVA, R.K., SRIVASTAVA, A.R., KORSMEYER, S.J., NESTEROVA, M., CHO-CHUNG, Y.S. and LONGO, D.L., Involvement of microtubules in the regulation of bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol., 18, 3509-3517 (1998).
76. STRAUSFELD, U., FERNANDEZ, A., CAPONY, J. P., GIRARD, F., LAUTREDOU, N., DERANCOURT, J., LABBE, J.C. and LAMB, N.J., Activation of p34cdc2 protein kinase by microinjection of human cdc25C into mammalian cells. Requirement for prior phosphorylation of cdc25C by p34cdc2 on sites phosphorylated at mitosis. J. biol. Chem., 269, 5989-6000 (1994).
77. STROBEL, T., SWANSON, L., KORSMEYER, S. and CANNISTRA, S.A., BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. nat. Acad. Sci. (Wash.), 93, 14094-14099 (1996).
78. TAKENAKA, K., MORIGUCHI, T. and NISHIDA, E., Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science, 280, 599-602 (1998).
79. TANG, C., WILLINGHAM, M.C., REED, J.C., MIYASHITA, T., RAY, S., PONNATHPUR, V., HUANG, Y., MAHONEY, M.E., BULLOCK, G. and BHALLA, K., High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia, 8, 1960-1969 (1994).
80. TISHLER, R.B., LAMPPU, D.M., PARK, S. and PRICE, B.D., Microtubule-active drugs, Taxol, vinblastine and nocodazole increase the levels of transcriptionally active p53. Cancer Res., 55, 6021-6025 (1995).
81. TORRES, K. and HORWITZ, S.B., Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58, 3620-3626 (1998).
82. TOURNEBIZE, R., ANDERSEN, S.S., VERDE, F., DOREE, M., KARSENTI, E. and HYMAN, A.A., Distinct roles of PP1 and PP2A-like phosphatases in control of microtubule dynamics during mitosis. EMBO J., 16, 5537-5549 (1997).
83. TRIELLI, M.O., ANDREASSEN, P.R., LACROIX, F.B. and MARGOLIS, R.L., Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific related mortality of transformed cells. J. Cell Biol., 135, 689-700 (1996).
84. WAHL, A.F., DONALDSON, K.L., FAIRCHILD, C., LEE, F.Y.F., FOSTER, S.A., DEMERS, G.W. and GALLOWAY, D.A., Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature (Med.), 2, 72-79 (1996).
85. WANG, H.-G., MIYASHITA, T., TAKAYAMA, S., SATO, T., TORIGOE, S., KRAJEWSKI, S., TANAKA, S., HOVEY, L., III, TROPPMAIR, J., RAPP, U.R. and REED, J.C., Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene, 9, 2751-2756 (1994).
86. WANG, H.G., RAPP, U.R. and REED, J.C., Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 87, 629-639 (1996).
87. WANG, T.-H., WANG, H.-S., ICHIJO, H., GIANNAKAKOU, P., FOSTER, J.S., FOJO, T. and WIMALASENA, J., Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathway. J. biol. Chem., 273, 4928-4936 (1998).
88. WEINSTEIN, J.N. AND 20 OTHERS, An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343-349 (1997).
89. WOLFSON, M., YANG, C.-P. and HORWITZ, S.B., Taxol induces tyrosine phosphorylation of SHC and its association with Grb2 in murine RAW 264.7 cells. Int. J. Cancer, 70, 248-252 (1997).
90. WOODS, C.M., ZHU, J., MCQUENEY, P.A., BOLLAG, D. and LAZARIDES, E., Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med., 1, 506-526 (1995).
91. WU, G.S. and EL-DEIRY, W.S., p53 and chemosensitivity. Nature (Med.), 2, 255-256 (1996).
92. YU, D.H., JING, T., LIU, B.L., YAO, J., TAN, M., MCDONNELL, T.J. and HUNG, M.C., Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21(Cip), which inhibits p34(Cdc2) kinase. Mol. Cell, 2, 581-591 (1998).
93. ZAFFARONI, N., SILVESTRINI, R., ORLANDI, L., BEARZATTO, A., GORNATI, D. and VILLA, R., Induction of apoptosis by Taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells. Brit. J. Cancer, 77, 1378-1385 (1998).
94. ZHANG, C.C., YANG, J.M., WHITE, E., MURPHY, M., LEVINE, A. and HAIT, W.N., The role of MAP4 expression in the sensitivity to paclitaxel and resistance to Vinca alkaloids in mutant cells. Oncogene, 16, 1617-1624 (1998).
95. ZHOU, R., OSKARSSON, M., PAULES, R.S., SCHULZ, N., CLEVELAND, D. and VANDE WOUDE, G.F., Ability of the c-mos product to associate with and phosphorylate tubulin. Science, 251, 671-678 (1991).
96. ZIOGAS, A., LORENZ, I.C., MOELLING, K. and RADZIWILL, G., Mitotic Raf-1 is stimulated independently of Ras and is active in the cytoplasm. J. biol. Chem., 273, 24108-24114 (1998).